VIDEO: LungART data could be ‘practice-changing’
In this video, James Stevenson, MD, a medical oncologist and hematologist at Cleveland Clinic, discussed data that came from the LungART trial, which was presented at ESMO Virtual Congress 2020.
With 4.5 years of follow-up data, the researchers reported post-operative radiotherapy for patients with completely resected non-small cell lung cancer (NSCLC), as well as N2 mediastinal N2 involvement, did not meet the primary endpoint of “improving disease-free survival,” according to Stevenson.
“It was a well-done randomized trial, which has to be looked at as practice-changing because prior to these results, most centers were routinely offering mediastinal radiation to patients who had N2-positive disease at the time of surgery,” he said.
References:
- Le Pechoux C, et al. Abstract LBA3_PR. Presented at: European Society for Medical Oncology Virtual Congress 2020; Sept. 19-21, 2020.
Collapse
Healio Interview
Read more about